Alcobra's metadoxine extended-release (MDX) already was walking a tightrope as a potential new therapeutic approach for adult ADHD, but a Phase III clinical trial miss reported Jan. 17 is leading the Israeli biotech to shutter that program and consider its strategic alternatives.
Alcobra revealed only a week earlier that it would conduct a six-month Phase I safety study of MDX to seek...